Primary Immune Deficiency (PID) - Market Insight, Epidemiology and Market Forecast - 2027

Publisher Name :
Date: 31-Jan-2018
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Primary Immune Deficiency (PID) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Primary Immune Deficiency (PID) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2027

Primary Immune Deficiency (PID) Understanding and Treatment Algorithm

The market report provides the overview of the Primary Immune Deficiency (PID) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Primary Immune Deficiency (PID) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Primary Immune Deficiency (PID) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Primary Immune Deficiency (PID) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Primary Immune Deficiency (PID) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Primary Immune Deficiency (PID) market.

Primary Immune Deficiency (PID) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Primary Immune Deficiency (PID) Report Insights

- Patient Population in Primary Immune Deficiency (PID)

- Therapeutic Approaches in Primary Immune Deficiency (PID)

- Primary Immune Deficiency (PID) Pipeline Analysis

- Primary Immune Deficiency (PID) Market Size and Trends

- Primary Immune Deficiency (PID) Market Opportunities

- Impact of upcoming Therapies in Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Primary Immune Deficiency (PID) Report Assessment

- Current Treatment Practices in Primary Immune Deficiency (PID)

- Unmet Needs in Primary Immune Deficiency (PID)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Primary Immune Deficiency (PID) market

- Organize sales and marketing efforts by identifying the best opportunities for Primary Immune Deficiency (PID) market

- To understand the future market competition in the Primary Immune Deficiency (PID) market.

Primary Immune Deficiency (PID) - Market Insight, Epidemiology and Market Forecast - 2027

Table of Contents

1. Report Introduction
2. Primary Immune Deficiency (PID) Market Overview at a Glance
2.1. Market Share Distribution of Primary Immune Deficiency (PID) in 2017
2.2. Market Share Distribution of Primary Immune Deficiency (PID) in 2027
3. Disease Background and Overview: Primary Immune Deficiency (PID)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Primary Immune Deficiency (PID) in 7MM
4.3. Total Prevalent Patient Population of Primary Immune Deficiency (PID) in 7MM - By Countries
5. Epidemiology of Primary Immune Deficiency (PID) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.1.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.1.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.1.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.1.6. Treatable Cases of the Primary Immune Deficiency (PID)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.4.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.4.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.4.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.4.6. Treatable Cases of the Primary Immune Deficiency (PID)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.5.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.5.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.5.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.5.6. Treatable Cases of the Primary Immune Deficiency (PID)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.6.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.6.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.6.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.6.6. Treatable Cases of the Primary Immune Deficiency (PID)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.7.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.7.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.7.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.7.6. Treatable Cases of the Primary Immune Deficiency (PID)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.8.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.8.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.8.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.8.6. Treatable Cases of the Primary Immune Deficiency (PID)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.9.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.9.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.9.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.9.6. Treatable Cases of the Primary Immune Deficiency (PID)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Primary Immune Deficiency (PID)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Primary Immune Deficiency (PID)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Primary Immune Deficiency (PID) : 7MM Market Analysis
12.1. 7MM Market Size of Primary Immune Deficiency (PID)
12.2. 7MM Percentage Share of drugs marketed for Primary Immune Deficiency (PID)
12.3. 7MM Market Sales of Primary Immune Deficiency (PID) by Products
13. Primary Immune Deficiency (PID) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Primary Immune Deficiency (PID) in United States
13.1.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in United States
13.1.3. Market Sales of Primary Immune Deficiency (PID) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Primary Immune Deficiency (PID) in Germany
13.2.1.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in Germany
13.2.1.3. Market Sales of Primary Immune Deficiency (PID) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Primary Immune Deficiency (PID) in France
13.2.2.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in France
13.2.2.3. Market Sales of Primary Immune Deficiency (PID) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Primary Immune Deficiency (PID) in Italy
13.2.3.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in Italy
13.2.3.3. Market Sales of Primary Immune Deficiency (PID) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Primary Immune Deficiency (PID) in Spain
13.2.4.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in Spain
13.2.4.3. Market Sales of Primary Immune Deficiency (PID) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Primary Immune Deficiency (PID) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in United Kingdom
13.2.5.3. Market Sales of Primary Immune Deficiency (PID) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Primary Immune Deficiency (PID) in Japan
13.3.2. Percentage Share of drugs marketed for Primary Immune Deficiency (PID) in Japan
13.3.3. Market Sales of Primary Immune Deficiency (PID) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 7: Treatable Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 12: Treatable Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 15: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 16: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 17: Treatable Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 22: Treatable Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 27: Treatable Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 31: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 32: Treatable Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Table 37: Treatable Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 42:7MM- Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 45: United States-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 48: Germany-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 51: France-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 54: Italy-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 57: Spain-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 60:UK-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Table 63: Japan-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Figure 7: Treatable Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Figure 8: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Figure 9: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Figure 10: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Figure 11: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Figure 12: Treatable Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Figure 13: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Figure 14: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Figure 15: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Figure 16: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Figure 17: Treatable Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Figure 18: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Figure 19: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Figure 20: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Figure 21: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Figure 22: Treatable Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Figure 27: Treatable Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Figure 28: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Figure 29: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Figure 30: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Figure 31: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Figure 32: Treatable Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Figure 33: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Figure 34: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Figure 35: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Figure 36: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Figure 37: Treatable Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 42:7MM- Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 43:7MM- Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 44: United States-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 45: United States-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 46: United States-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 47: Germany-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 48: Germany-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 49: Germany-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 50: France-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 51: France-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 52: France-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 53: Italy-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 54: Italy-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 55: Italy-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 56: Spain-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 57: Spain-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 58: Spain-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 59:UK-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 60:UK-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 61:UK-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 62: Japan-Market Size of Primary Immune Deficiency (PID) in USD MM (2016-2027)
Figure 63: Japan-Market Share Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
Figure 64: Japan-Market Sales of Primary Immune Deficiency (PID) by Therapies in USD MM (2016-2027)
  • Global Sclerotherapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 11-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids. Scope of the Report: This report focuses on the Sclerotherapy in g......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sclerotherapy Market 2018, Forecast to 2023
    Published: 11-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids. Scope of the Report: This report focuses on the Sclerotherapy in g......
  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 09-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radioactive sources into the treatment site, to avoid risk of radiation exposure to clinical staff. Brachytherapy Seeds is radiation sources enclosed within a non-radioactive capsule. The common radiation sources are Iodine-125 Palladium-103 Cesium-137. Scope of the Report: This report focuses on the Brachytherapy Afterloaders, Brachytherapy Seeds in global market, especially in N......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Brachytherapy Afterloaders, Brachytherapy Seeds Market 2018, Forecast to 2023
    Published: 09-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radioactive sources into the treatment site, to avoid risk of radiation exposure to clinical staff. Brachytherapy Seeds is radiation sources enclosed within a non-radioactive capsule. The common radiation sources are Iodine-125 Palladium-103 Cesium-137. Scope of the Report: This report focuses on the Brachytherapy Afterloaders, Brachytherapy Seeds in global market, especially in N......
  • Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market
    Published: 01-Jun-2018        Price: US 4995 Onwards        Pages: 125
    Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common symptoms of psoriasis include inflammation, swelling, and patches of red, itchy, flaky skin called skin lesions. The most common sites of involvement are the scalp, elbows and knees, followed by nails, hands, feet and trunk. It is estimated tha......
  • Global Acute Ischemic Stroke Therapeutics Market Professional Survey Report 2018
    Published: 01-Jun-2018        Price: US 3500 Onwards        Pages: 104
    This report studies Acute Ischemic Stroke Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bayer - Boehringer Ingelheim - Roche - Sanofi......
  • Systemic Lupus Erythematosus - Pipeline Review, H1 2018
    Published: 31-May-2018        Price: US 2000 Onwards        Pages: 446
    Systemic Lupus Erythematosus - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape. "Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the......
  • Global Human Microbiome Therapeutics Market Research Report 2018
    Published: 29-May-2018        Price: US 2900 Onwards        Pages: 109
    This report studies the global Human Microbiome Therapeutics market status and forecast, categorizes the global Human Microbiome Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. In 2017, the global Human Microbiome Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, wit......
  • Global Human Microbiome Therapeutics Sales Market Report 2018
    Published: 29-May-2018        Price: US 4000 Onwards        Pages: 109
    This report studies the global Human Microbiome Therapeutics market status and forecast, categorizes the global Human Microbiome Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). In 2017, the global Human Microbiome Therapeutics market size was xx million US$ and it is expected ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs